Keros Therapeutics Authorizes Up to $5 Million Share Buyback
Keros Therapeutics’ board approved a share buyback of up to $5 million after the company received a $20 million development milestone payment from Takeda Pharmaceuticals under a licensing agreement.
November 17, 2026, 01:46 AM 688 0
The payment is tied to elritercept, which Keros is developing as a blood platelet producer. The drug reached a clinical-trial milestone with the first patient completing dosing.
Keros said the buyback authorization may be modified or discontinued at any time.
Comments (0)
No comments yet. Be the first!